Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Trial to Determine MTD of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours and Later a Weekly Dosing Schedule in Selected Tumour Types

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01317420
First received: March 15, 2011
Last updated: May 27, 2016
Last verified: May 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2016
  Primary Completion Date: February 2016 (Final data collection date for primary outcome measure)